IP Library › Granted Patent US 6,972,299
Granted Patent B2
US 6,972,299 · App. 10/396,172 · Granted Dec 6, 2005

Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles

Assignee: Hoffmann-La Roche Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,972,299
App. No.
10/396,172
Granted
Dec 6, 2005
Kind
B2
Abstract

This invention relates to a compound and the use of the compound of the formula wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description, A signifies —CH═CH— or —C≡C—; and B signifies wherein R 6 to R 26 , X and Y are as defined in the specification or a pharmaceutically acceptable salt thereof, for use in pharmaceutical compositions for the treatment or prevention of mGluR5 receptor mediated disorders.

Claims (41)

1. A compound of formula

wherein

R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of hydrogen, lower alkyl, —(CH 2 ) n -halogen, lower alkoxy, —(CH 2 ) n —NRR′, —(CH 2 ) n —N(R)—C(O)-lower alkyl, or aryl;

R, R′ and R″ are independently selected from the group consisting of hydrogen and lower alkyl;

R 6 is selected from the group consisting of lower alkyl, —(CH 2 ) n —C(O)OR and halogen;

R 7 is selected from the group consisting of lower alkyl, —(CH 2 ) n —C(O)OR′, halogen, and nitro; and

R 8 is selected from the group consisting of hydrogen, lower alkyl, —(CH 2 ) n —OH, —(CH 2 ) n —C(O)OR″ or aryl;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , wherein R 7 signifies lower alkyl or —(CH 2 ) n —C(O)OR′.

3. The compound according to claim 1 , which is 4,5-diisopropyl-1-methyl-2-styryl-1H-imidazole.

4. The compound according to claim 1 , which is 2-[2-(4-fluoro-phenyl)-vinyl]-4,5-diisopropyl-1-methyl-1H-imidazole.

5. The compound according to claim 1 , which is 2-[2-(4-chloro-phenyl)-vinyl]-4,5-diisopropyl-1-methyl-1H-imidazole.

6. The compound according to claim 1 , which is 2-[2-(4-butoxy-phenyl)-vinyl]-4,5-diisopropyl-1-methyl-1H-imidazole.

7. The compound according to claim 1 , which is 4,5-diisopropyl-2-[2-(4-methoxy-2,3,6-trimethyl-phenyl)-vinyl]-1-methyl-1H-imidazole.

8. The compound according to claim 1 , which is 4,5-diisopropyl-2-[2-(4-methoxy-phenyl)-vinyl]-1-methyl-1H-imidazole.

9. The compound according to claim 1 , which is 2-[2-(4-chloro-3-fluoro-phenyl)-vinyl]-4,5-diisopropyl-1-methyl-1H-imidazole.

10. The compound according to claim 1 , which is 2-[2-(4-ethoxy-phenyl)-vinyl]-4,5-diisopropyl-1-methyl-1H-imidazole.

11. The compound according to claim 1 , which is 4,5-diisopropyl-1-methyl-2-[2-(2,3,4-trimethoxy-phenyl)-vinyl]-1H-imidazole.

12. The compound according to claim 1 , which is 2-[2-(2,4-dichloro-phenyl)-vinyl]-4,5-diisopropyl-1-methyl-1H-imidazole.

13. The compound according to claim 1 , which is 4,5-diisopropyl-1-methyl-2-(2-p-tolyl-vinyl)-1H-imidazole.

14. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula

wherein

R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of hydrogen, lower alkyl, —(CH 2 ) n -halogen, lower alkoxy, —(CH 2 ) n —NRR′, —(CH 2 ) n —N(R)—C(O)-lower alkyl, or aryl;

R, R′ and R″ are independently selected from the group consisting of hydrogen and lower alkyl;

R 6 is selected from the group consisting of lower alkyl, —(CH 2 ) n —C(O)OR and halogen;

R 7 is selected from the group consisting of lower alkyl, —(CH 2 ) n —C(O)OR′, halogen, and nitro; and

R 8 is selected from the group consisting of hydrogen, lower alkyl, —(CH 2 ) n —OH, —(CH 2 ) n —C(O)OR″ or aryl;

or a pharmaceutically acceptable salt thereof in a racemic or optically active form and a pharmaceutically inert carrier.

15. A pharmaceutical composition according to claim 14 wherein the compound is selected from the group consisting of

4,5-diisopropyl-1-methyl-2-styryl-1H-imidazole,

2-[2-(4-fluoro-phenyl)-vinyl]-4,5-diisopropyl-1-methyl-1H-imidazole,

2-[2-(4-chloro-phenyl)-vinyl]-4,5-diisopropyl-1-methyl-1H-imidazole,

2-[2-(4-butoxy-phenyl)-vinyl]-4,5-diisopropyl-1-methyl-1H-imidazole,

4,5-diisopropyl-2-[2-(4-methoxy-2,3,6-trimethyl-phenyl)-vinyl]-1-methyl-1H-imidazole,

4,5-diisopropyl-2-[2-(4-methoxy-phenyl)-vinyl]-1-methyl-1H-imidazole,

2-[2-(4-chloro-3-fluoro-phenyl)-vinyl]-4,5-diisopropyl-1-methyl-1H-imidazole,

2-[2-(4-ethoxy-phenyl)-vinyl]-4,5-diisopropyl-1-methyl-1H-imidazole,

4,5-diisopropyl-1-methyl-2-[2-(2,3,4-trimethoxy-phenyl)-vinyl]-1H-imidazole,

2-[2-(2,4-dichloro-phenyl)-vinyl]-4,5-diisopropyl-1-methyl-1H-imidazole and

4,5-diisopropyl-1-methyl-2-(2-p-tolyl-vinyl)-1H-imidazole.

16. A pharmaceutical composition according to claim 14 wherein the compound is 4,5-diisopropyl-1-methyl-2-[2-(2,3,4-trimethoxy-phenyl)-vinyl]-1H-imidazole.

Priority Claims (1)
EP 00126615 · Dec 4, 2000 · regional
Continuity (2)
Division 0999664100 · Nov 28, 2001
Related Publication 20030208082A1 · Nov 6, 2003